A recent Endocrinology digest,
as sent to subscribers

Study Type: Commentary/perspective article (summarising the DASH4D RCT and prior DASH evidence; not original research)

Key Question: Should a specific evidence-based dietary pattern, DASH4D, be recommended as the starting point for individualised nutrition therapy in diabetes?

Key Findings:

• Argues that the 2026 ADA Standards of Care recommend individualised nutrition therapy without endorsing a specific dietary pattern, leaving clinicians without a clear starting point.
• Cites DASH4D, a modified DASH diet for adults with diabetes, as reducing blood pressure and improving glycaemic control in people with type 2 diabetes and hypertension.
• Concludes DASH4D should be a recommended diet alongside individualised counselling. The abstract gives no effect sizes, confidence intervals, or trial details.

Clinical Relevance: Provides a trial-supported dietary framework that could inform structured education and dietitian-led advice for type 2 diabetes with hypertension, though NICE guidance does not currently specify a single pattern.

Limitations: As an opinion piece, it offers no new data, and the abstract does not report effect sizes, so benefit and generalisability to UK populations and food environments remain unquantified.

Study Type: Secondary analysis of an RCT (DiGest); observational, baseline cross-sectional/cohort comparison of self-reported dietary intake.

Key Question: Is low or very low carbohydrate intake in GDM associated with altered nutrient adequacy, glycaemia, or perinatal outcomes, given guidance recommending ≥175 g/day?

Key Findings:

• Of 215 women, 30.7% reported ≥175 g/day, 34.4% 120–175 g/day, and 34.9% <120 g/day. Lower carbohydrate intake coincided with lower energy, fibre, B vitamin, vitamin E and mineral intake.
• <120 g/day was associated with lower time above range >120 mg/dL (−6.8%, 95% CI −13.4 to −0.2) and lower birthweight (−9.6 centiles, 95% CI −18.7 to −0.6), with no difference in LGA/SGA.
• Low carbohydrate proportion of energy (<35%) without energy restriction reduced TAR but did not change birthweight.

Clinical Relevance: Informs dietetic advice in GDM, suggesting lower carbohydrate intake improves glycaemia, but micronutrient and fibre adequacy need active monitoring.

Limitations: Single 24-hour dietary recall at baseline is a weak measure of habitual intake, and findings are observational with borderline-significant associations and likely residual confounding.

Study Type: Long-term follow-up (median 11 years, maximum 14) of pooled randomised trials (ARMMS-T2D), with post-hoc predictor analysis using time-to-event methods and LASSO.

Key Question: Which baseline characteristics predict T2D remission and subsequent relapse after metabolic-bariatric surgery (MBS) versus intensive medical-lifestyle therapy?

Key Findings:

• Remission (HbA1c <6.5% off glucose-lowering medication) occurred in 58% of MBS participants (n=166) versus 3% with medical-lifestyle management (n=96).
• Multivariate predictors of remission: shorter diabetes duration, no baseline insulin use, and greater weight change at 1 year (all P<0.01).
• Relapse after initial remission in the MBS group was predicted by longer baseline diabetes duration and more glucose-lowering medication classes.

Clinical Relevance: Supports earlier surgical referral for T2D with obesity in NHS pathways, and helps counsel patients on likelihood and durability of remission.

Limitations: Modest sample size, pooled heterogeneous procedures and trials, and predictor analyses were not randomised comparisons, limiting generalisability to current UK practice.

Study Type: Preclinical in vitro mechanistic study (human iPSC differentiation model with CRISPR/Cas9 knockout, bulk and single-cell RNA-seq).

Key Question: What role does gastrin/CCK signalling via CCKBR play in human definitive endoderm specification and pancreatic endocrine versus ductal fate decisions?

Key Findings:

• CCKBR expression peaked at definitive endoderm, declined through differentiation, and was largely absent in endocrine cells; GAST and CCK were expressed only transiently in progenitor and endocrine stages.
• CCKBR knockout shifted cells towards ectodermal and mesodermal transcriptional programmes and reduced pancreatic lineage specification.
• Sustained CCKBR activation reduced endocrinogenesis and promoted epithelial and ductal-like cell formation.

Clinical Relevance: No direct clinical application yet, but it may inform optimisation of stem cell-derived beta-cell protocols relevant to future cell replacement therapy for diabetes.

Limitations: Findings derive solely from in vitro iPSC models, so relevance to in vivo human pancreatic development or disease remains unestablished (abstract gives no quantitative effect sizes).

Study Type: Prospective matched controlled cohort study (single-centre, small sample)

Key Question: Are lower breastfeeding rates in women with type 2 diabetes explained by type 2 diabetes itself or by co-existing obesity?

Key Findings:

• At 4 months, full breastfeeding rates were 24% (T2DM), 38% (BMI-matched controls) and 64% (normal-BMI controls); T2DM vs BMI-matched p=0.26, vs normal BMI p=0.002.
• Any breastfeeding rates were 55%, 54% and 82% respectively; T2DM vs BMI-matched p=0.79, vs normal BMI p=0.03.
• Breastfeeding outcomes in T2DM mirrored BMI-matched normoglycaemic women, suggesting obesity is the main driver.

Clinical Relevance: Breastfeeding support for women with T2DM in UK antenatal and postnatal pathways should address obesity-related barriers, not just diabetes-specific factors.

Limitations: Only 28-29 women per group, so the study is underpowered to confirm no difference between T2DM and BMI-matched controls (the abstract does not report confidence intervals or adjusted analyses).

Study Type: Prospective cross-sectional study (n=1446), primary care and endocrinology/diabetes clinics; US-based authorship, setting not stated in abstract.

Key Question: Which metabolic factors (obesity, adipose tissue dysfunction, insulin resistance) determine clinically significant liver fibrosis (≥F2) across the glycaemic spectrum in MASLD?

Key Findings:

• MASLD prevalence rose stepwise: 39% (normoglycaemia), 55% (prediabetes), 68% (T2DM). Significant fibrosis was 1%, 6% and 12% respectively, but did not track BMI/glycaemia stepwise.
• Fibrosis was rare in lean/overweight prediabetes; risk rose fourfold with obesity, especially with severe adipose tissue and systemic insulin resistance. Obesity plus T2DM carried the highest prevalence (16%), again mainly with insulin resistance.
• Most participants with significant fibrosis were in the top two quintiles of Adipo-IR or HOMA-IR.

Clinical Relevance: Suggests HOMA-IR could refine fibrosis risk stratification in primary care beyond glycaemic status alone, relevant to targeting FibroScan referral in UK pathways.

Limitations: Cross-sectional design precludes causal inference, and fibrosis was defined by elastography thresholds with confirmatory imaging/biopsy only when ≥F2 was suspected.

Study Type: Cross-sectional reference interval analysis within a large population-based cohort (n=6,671; oversampled for BMI >27 kg/m²), following CLSI EP28-A3c.

Key Question: Does BMI warrant partitioning of estradiol and estrone reference intervals in middle-aged men and postmenopausal women?

Key Findings:

• Sex was the strongest partitioning factor, followed by menopausal status in women.
• Under a shared interval, values above the upper limit (ideal 2.5%) were 4.9% (estradiol) and 5.2% (estrone) in men with obesity, and 11.4% and 7.7% in postmenopausal women with obesity.
• In postmenopausal women, upper reference limits for normal weight, overweight and obesity were 138, 157 and 210 pmol/L (estradiol) and 32, 41 and 74 pmol/L (estrone).

Clinical Relevance: Estradiol or estrone results from postmenopausal women with obesity, or men with obesity, may be over-flagged as abnormal using standard laboratory intervals, so BMI should inform interpretation until labs adopt stratified ranges.

Limitations: The abstract does not state the assay method (e.g., immunoassay vs LC-MS/MS), and the cohort is middle-aged and BMI-oversampled, so generalisability to other ages, ethnicities and assay platforms is uncertain.

Study Type: Post hoc analysis of two open-label phase 3 trials (POMC: NCT02896192; LEPR: NCT03287960).

Key Question: Does setmelanotide improve metabolic parameters and metabolic syndrome severity in patients with severe obesity due to POMC or LEPR deficiency?

Key Findings:

• Of 21 enrolled patients, 18 had complete data. Baseline means were largely normal except weight measures, fasting glucose and triglycerides; mean MetS-Z-BMI score was 1.49 (SD 1.33).
• At ~52 weeks, most patients improved in at least one metabolic parameter; mean MetS-Z-BMI change was -1.05 (SD 0.88).
• Greater MetS-Z-BMI reductions occurred in patients meeting weight-based response thresholds versus non-achievers (P=.0187) and in POMC versus LEPR deficiency (P=.0278).

Clinical Relevance: For the small NHS cohort eligible for setmelanotide, this suggests benefit beyond weight loss, which may inform treatment-response monitoring and commissioning discussions.

Limitations: Very small sample, no control group, and post hoc subgroup analyses, so findings are exploratory and cannot establish causality.